Physician profile
John A Dilullo
NPI 1427020460
$3,893.34
in general payments reported to CMS, 2019-2025
31 companies · $85.77 in 2025
The $85.77 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $239 · 2021: $414 · 2022: $919 · 2023: $1,047 · 2024: $837 · 2025: $85.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,969.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $803.51 | 2021-2024 | Qulipta, Botox, Ubrelvy |
| Biohaven Pharmaceutical Holding Company LTD. | $570.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $394.30 | 2019-2025 | |
| Genentech USA, INC. | $288.80 | 2020-2024 | Ocrevus |
| Validus Pharmaceuticals LLC | $265.72 | 2023-2024 | Equetro |
| Biohaven Pharmaceuticals, INC. | $246.26 | 2021 | |
| Emd Serono, INC. | $234.66 | 2019-2020 | |
| Biogen, INC. | $143.05 | 2023-2025 | Vumerity, Tysabri, Avonex |
| Teva Pharmaceuticals USA, INC. | $118.68 | 2019-2024 | Austedo Xr |
| Pfizer INC. | $100.52 | 2023-2024 | |
| Celgene Corporation | $93.88 | 2022-2024 | Zeposia |
| Amgen INC. | $72.43 | 2022-2023 | Aimovig |
| Otsuka America Pharmaceutical, INC. | $65.42 | 2023-2024 | Rexulti |
| Tanabe Pharma America, INC. | $56.69 | 2023-2024 | |
| Allergan, INC. | $49.87 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $41.38 | 2020-2024 | |
| Lilly USA, LLC | $36.62 | 2022-2024 | Emgality |
| Janssen Pharmaceuticals, INC | $36.27 | 2021-2022 | |
| Argenx US, INC. | $31.63 | 2023 | Vyvgart |
| Genzyme Corporation | $29.62 | 2022 | |
| Alnylam Pharmaceuticals INC. | $28.81 | 2023 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $28.29 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $22.81 | 2024 | Hyqvia |
| Alexion Pharmaceuticals, INC. | $20.67 | 2024 | Ultomiris |
| Novo Nordisk INC | $20.29 | 2024 | Ozempic |
| Ge Healthcare | $19.73 | 2021 | |
| Mdd US Operations, LLC | $16.50 | 2023 | Gocovri |
| Sunovion Pharmaceuticals INC. | $14.89 | 2020 | |
| Lundbeck LLC | $14.29 | 2024 | Rexulti |
| Adamas Pharmaceuticals, INC. | $13.70 | 2020 | |
| Acorda Therapeutics, INC | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dilullo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.